Boehringer Ingelheim in association with infill Kommunikation GmbH
Gilead Sciences in association with iS Health
Thermo Fisher Scientific in association with Open LEC
Boehringer Ingelheim in association with infill Kommunikation GmbH
Boehringer Ingelheim’s (BI) global digital strategy for the oncology franchise is an interconnected and multichannel approach offering quality medical information and education to different target groups, while working under tight legal restrictions for communicating not-yet licensed drugs. Target groups of interest are opinion leaders, healthcare professionals, the media and patients.
The main components of the strategy are:
All the websites were developed with a CMS (content management system) backend to enable consistency in design, structure and contents used for spinoffs by regional BI affiliates.
BI’s digital strategy is synergistic and successful in reaching the target audiences, while positioning BI as a trusted name in the world of oncology.
Executive summary as submitted
"Boehringer Ingelheim’s digital strategy for its oncology franchise was chosen because of the breadth of information available with a high level of consistency to the materials. It took a genuine ecosystem approach that ambitiously addressed multiple stakeholders in a creative and innovative way, offering a useful ability to tailor materials."